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List of Abbreviations 34 
ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs 35 
ALT: Alanine Aminotransferase 36 
APRI: AST to Platelet Ratio Index 37 
AST: Aspartate Aminotransferase 38 
AUROC: Area under receiver operating curve 39 
BMI: Body mass index 40 
ECM: Extracellular matrix 41 
ELISA: Enzyme-linked immunosorbent assay 42 
GGT: Gamma-Glutamyltransferase 43 
HDL: High-density lipoprotein 44 
LDL: Low-density lipoprotein 45 
LHR+: Positive likelihood ratio  46 
LHR-: Negative likelihood ratio 47 
MS: Metabolic syndrome 48 
NAFL: Non-alcoholic fatty liver 49 
NAFLD: Non-alcoholic fatty liver disease 50 
NASH: Non-alcoholic steatohepatitis 51 
NFS: NAFLD Fibrosis Score 52 
NPV: Negative predictive value 53 
PPV: Positive predictive value 54 
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Abstract  59 
Background and Aim: Given the high global prevalence of non-alcoholic fatty liver disease (NAFLD), the 60 
need for relevant non-invasive biomarkers and algorithms to accurately stage disease severity is a critical 61 
unmet medical need. Identifying those with advanced fibrosis (≥F3) is the most crucial, as these individuals 62 
have the greatest risk of adverse, long-term, liver-related outcomes. We aimed to investigate the role of 63 
PRO-C3 (a marker of type III collagen formation) as a biomarker for advanced fibrosis in NAFLD. Methods: 64 
We measured PRO-C3 by enzyme-linked immunosorbent assay (ELISA) in two large independent cohorts 65 
with extensive clinical phenotyping and liver biopsy; 150 in the derivation and 281 in the validation cohort. 66 
A PRO-C3 based fibrosis algorithm that included Age, presence of DiAbetes, PRO-C3 (a marker of type III 67 
collagen formation), and plaTelet count (“ADAPT”) was developed. Results: PRO-C3 increased with fibrosis 68 
stage (rho 0.50 p<0.0001) and was independently associated with advanced fibrosis (OR=1.05, 95% CI 1.02-69 
1.08, p= 0.003). ADAPT showed areas under the receiver operating characteristics curve (AUROC) of 0.86 70 
(95% CI 0.79 to 0.91) in the derivation and 0.87 in the validation cohort (95% CI 0.83 to 0.91) for advanced 71 
fibrosis. This was superior to the existing fibrosis scores, aspartate aminotransferase (AST) to platelet ratio 72 
index (APRI), FIB-4 and NAFLD fibrosis score (NFS) in most comparisons. Conclusion: PRO-C3 is an 73 
independent predictor of fibrosis stage in NAFLD. A PRO-C3 based score (ADAPT) accurately identifies 74 
patients with NAFLD and advanced fibrosis and is superior to APRI, FIB-4 and NFS. 75 
 76 
Keywords 77 
Biomarker, Extracellular matrix, Non-invasive score, Non-alcoholic fatty liver disease, PRO-C3 78 
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Introduction 79 
The increase in global prevalence of metabolic syndrome (MS) has been accompanied by a rise in organ 80 
damage including end stage disease related to non-alcoholic fatty liver disease (NAFLD). Estimates place the 81 
worldwide prevalence of NAFLD at 25% 
1
. A subset of these patients develop non-alcoholic steatohepatitis 82 
(NASH) that can progress to cirrhosis and are at a high risk of adverse liver-related outcomes
1
. From a 83 
management and therapeutic perspective, an unmet clinical need is the requirement to distinguish those 84 
with early disease from those at highest risk of clinical complications. While metabolic hepatic 85 
inflammation is the milieu that drives disease progression, various studies (including meta analyses) that 86 
have examined for prognostic histological features suggest that fibrosis stage is the parameter that best 87 
associates with overall- and liver-related mortality, as well as liver transplantation and liver related events
2–
88 
5
.  89 
The gold standard for the evaluation of liver fibrosis stage is percutaneous needle biopsy, which is 90 
compromised by inherent sampling and inter-observer biases and peri-procedural risk
6,7
. The invasiveness 91 
and costs of performing biopsies also makes it unsuitable for mass screening, for staging and risk 92 
stratification. The latter is important as the majority of patients with advanced fibrosis and even cirrhosis, 93 
are asymptomatic and often indistinguishable from those at earlier disease stages
8,9
. In this context, there 94 
is a need for surrogate markers of disease stage that can identify and risk stratify patients with NAFLD. This 95 
area of research can broadly be divided into liquid (typically blood based) or physical approaches 96 
(measurement of liver stiffness). Physical approaches while promising are less useful for population level 97 
screening and are limited by cost and other technique-specific considerations. Several serum based 98 
biomarker tests have previously been developed and applied to NAFLD patients
10–14
. These scores typically 99 
combine clinical features and routine laboratory tests and are used primarily to rule out advanced fibrosis
15
, 100 
however they lack sufficient diagnostic accuracy and sensitivity.  101 
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Liver fibrosis is characterized by the accumulation of excess extracellular matrix (ECM) and hence 102 
biomarkers reflecting structural changes occurring in the hepatic ECM during chronic injury may be of value 103 
in the assessment of fibrosis progression or regression. We recently demonstrated that PRO-C3, an 104 
ADAMTS generated neo-epitope marker of type III collagen formation, is a marker of fibrosis in patients 105 
with chronic hepatitis C. The role of PRO-C3 in patients with NAFLD however, is largely unknown. Since the 106 
performance of biomarkers and non-invasive liver fibrosis scores varies widely according to disease etiology, 107 
whether PRO-C3 has a role as a biomarker in NAFLD is unclear. In this study, we sought to a) explore the 108 
association of PRO-C3 with liver fibrosis in two large independent biopsy-proven cohorts with NAFLD and b) 109 
determine if PRO-C3 can be combined with simple and routinely available clinical variables in to a novel 110 
score for the prediction of advanced fibrosis in patients with NAFLD. We compared the performance of our 111 
derived model with other known biomarker algorithms. 112 
 113 
   114 
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Materials and Methods 115 
Study population 116 
A total of 431 well phenotyped patients with biopsy confirmed NAFLD comprised the study cohort. The 117 
derivation cohort included 150 patients from the Storr Liver Centre, Sydney, Australia; the validation cohort 118 
comprised 281 patients recruited from four international sites, Nottingham University Hospitals NHS Trust, 119 
United Kingdom (n=42); Kurume University School of Medicine, Kurume, Japan (n=48); University of 120 
Western Australia, Nedlands, Australia (n=144) and 47 additional patients from the Storr Liver Centre.  121 
All patients were referred for the investigation of abnormal liver tests or steatosis detected by ultrasound. 122 
The diagnosis of NAFLD was established by liver biopsy in all cases. Patients with disease of other etiologies 123 
including viral hepatitis and auto-immune liver disease were excluded by standard clinical, laboratory and 124 
histopathological assessments. Patients with evidence of hepatic decompensation, secondary causes of 125 
steatosis, including excess alcohol (men, >30 g/day; women, >20 g/day), total parenteral nutrition or the 126 
use of drugs known to precipitate steatosis were excluded.  127 
Demographic and clinical data were obtained, including age, gender, ethnicity, height, weight, and waist 128 
circumference at the time of biopsy. Body mass index (BMI) was calculated as BMI = kg/m
2
. Arterial 129 
hypertension was defined as blood pressure ≥130/≥85 mmHg or treatment with antihypertensive drugs. 130 
Diabetes was defined as a fasting blood glucose ≥7.0 mmol/L, previous diagnosis of diabetes or use of anti-131 
diabetic drugs. Hyperlipidemia was defined as fasting total cholesterol >5.5 mmol/L, triglycerides >1.7 132 
mmol/L or treatment with lipid-lowering drugs. Ethical approval and written informed consent from 133 
patients was obtained from all participating centers.  134 
Histology  135 
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All biopsies were routinely stained with hematoxylin & eosin and Masson’s Trichrome. The stained sections 136 
were read and scored by an expert liver pathologist at each participating center using the scoring system 137 
proposed by Kleiner et al., 2005
16
. The stage of liver fibrosis was defined as: stage 0, absence of fibrosis; 138 
stage 1, perisinusoidal or portal fibrosis; stage 2 perisinusoidal and portal/periportal fibrosis; stage 3 septal 139 
or bridging fibrosis; and stage 4 as cirrhosis. A diagnosis of NASH was according to the EASL-EASD-EASO 140 
guidelines.
17
 Thirty-one biopsies were scored independently by pathologists from the various centers, and 141 
inter observer agreement was calculated using the κ statistic and was =0.55 for fibrosis, comparable to 142 
previously published results
18–21
.  143 
Biomarker quantification 144 
At the time of biopsy, a fasting blood sample was obtained and routine biochemical tests were performed 145 
using standard methods and assays. Biochemical tests included albumin, alanine aminotransferase (ALT), 146 
aspartate aminotransferase (AST), total cholesterol, gamma-glutamyltransferase (GGT), insulin, high-147 
density lipoprotein (HDL), low-density lipoprotein (LDL), platelets, and triglycerides.  Additional blood 148 
samples were drawn and frozen at −80°C for future research. Type III collagen formation was assessed in 149 
serum using the PRO-C3 competitive ELISA assay from Nordic Bioscience, Herlev, Denmark, as previously 150 
described
22
.  151 
The APRI, FIB-4 and NAFLD Fibrosis Scores were calculated using clinical and routine laboratory variables 152 
and previously defined algorithms and cut-off values for NAFLD/NASH patients
10,12,14,23
.  153 
Statistical analysis 154 
The main aim of this study was the development of an algorithm comprised of clinical and laboratory 155 
variables that could accurately distinguish patients with advanced fibrosis (F≥3) from those without. To this 156 
end, patients in the derivation cohort were stratified into those with advanced fibrosis (F≥3) and those 157 
without (F0-2). Stage 2 and 3 for lobular and portal inflammation was pooled as only 1 patient in both 158 
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groups was graded stage 3. Continuous variables in the two groups were compared using the t test and 159 
categorical variables were compared using Fisher’s exact test. Comparisons between mean marker levels 160 
were performed using the Kruskal-Wallis test followed by Dunn’s multiple comparison test. Variables that 161 
were significantly different between patients with advanced fibrosis and those without advanced fibrosis 162 
were identified as potential algorithm components.  163 
For the formulation of predictive models, variables showing a p <0.05 at univariate analysis (Student t test 164 
for parametric variables, and X
2
 or Fisher exact test for frequencies) were included. The interaction 165 
between these variables was first tested. Variables explaining a statistically significant proportion of the 166 
variance (p <0.05) were maintained in the model using the likelihood ratio (LR) test. The model variables 167 
were selected using the leave-one-out method to facilitate the calculation of over-fit bias reduced 168 
estimates
24
. To avoid over-fitting, 10-fold cross validations were used in the tree building process. 169 
The model was as following: 170 
 =  	
	 	 × 	⎯3√

  +  
The discriminative ability of the model for the identification of severe fibrosis (F≥3) was assessed by means 171 
of receiver operating characteristic curve analysis and expressed as area under the receiver operating 172 
characteristic curve (AUROC). A cut-off value to distinguish patients with advanced fibrosis from those 173 
without was determined using the bootstrap Youden Index. The diagnostic accuracy of the algorithm and 174 
the derived cut-off was determined by calculating sensitivity, specificity, positive predictive value (PPV) and 175 
negative predictive value (NPV). To overcome both spectrum effect and ordinal scale issues, we undertook 176 
two approaches. Firstly, we used the Obuchowski measure, as proposed by Lambert et al
25,26
, which is a 177 
measure of the probability that two randomly chosen patients from different fibrosis stages are correctly 178 
classified according to the weighted scheme, with a penalty for incorrect classification. In the second 179 
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method, we standardized the AUROC for the distribution of fibrosis stages as proposed by Poynard et al
27
, 180 
as recently described
28
. 181 
ROC curves were also calculated for the established diagnostic scores, APRI, FIB-4 and NAFLD Fibrosis Score. 182 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative 183 
likelihood ratio (LHR
+
, LHR
−
) and 95% CIs were calculated. Estimates of AUROCs and comparisons between 184 
AUROCs were performed using the method suggested by Hanley and McNeil
29
. Validation was subsequently 185 
performed on the validation cohort as well as for the combined overall cohort.  186 
All data are shown as medians and variation expressed via Tukey plots. P-values <5% were considered 187 
significant. Model building and statistical analysis was performed using MedCalc version 16.8.4 (MedCalc 188 
Software, Ostend, Belgium) and SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). Graphs were designed 189 
using GraphPad Prism version 7 (GraphPad Software, Inc., CA, USA).   190 
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Results 191 
Patient Characteristics 192 
The characteristics of the 150 NAFLD patients used to develop the model (derivation cohort) and the 281 193 
used to test the model (validation cohort) are shown in Table 1. Serum levels of albumin, AST, cholesterol 194 
and HDL were all significantly lower in the validation cohort when compared to the derivation cohort. In 195 
addition, both BMI and insulin level were found to be significantly elevated. No other significant differences 196 
were observed between the two cohorts. The prevalence of severe fibrosis was not significantly different 197 
between the cohorts. 198 
PRO-C3 is highly associated with severity of fibrosis and histological parameters 199 
Within the derivation cohort, a neo-epitope marker of type III collagen formation, PRO-C3, was found to be 200 
significantly elevated in patients with advanced fibrosis (F≥3) compared to the mild/moderate group 201 
(p<0.0001). PRO-C3 was highly associated with disease severity (Figure 1) and moderately correlated to the 202 
severity of fibrosis (rho = 0.501, p<0.0001). PRO-C3 was able to discriminate between the following stages 203 
of fibrosis (Figure 1): F0 versus F2 (27% increase, p<0.0332), F0 versus F3 (54% increase, p<0.0001), F1 204 
versus F3 (36% increase, p<0.0002) and F0 versus F4 (57% increase, p<0.0021). In addition, PRO-C3 205 
discriminated between the various stages of hepatocyte ballooning (stage 0 versus stage 1 p=0.001, stage 0 206 
versus 2 p=0.0003), lobular inflammation (stage 0 versus stage 1 p=0.0004, stage 0 versus stage 2 and 3 207 
p=0.0008) and steatosis (stage 1 versus stage 3 p=0.003).  208 
We undertook logistic regression to discern the effect of various clinical variables on the association of 209 
PRO-C3 with the presence of advanced fibrosis (F≥3) within the derivation cohort. In this analysis, PRO-C3, 210 
when adjusted for age, ALT, AST, BMI, ballooning, lobular inflammation, presence of diabetes, GGT and 211 
platelet count, was independently associated with advanced fibrosis (OR=1.054, 95% CI 1.01-1.07) (Table 2). 212 
Page 11 of 51
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
The area under the receiver-operating curve (AUROC) for the identification of patients with advanced 213 
fibrosis (F≥3) of PRO-C3 alone was 0.81 (95% CI 0.74-0.87) (Data not shown).  214 
Clinical parameters associated with the level of PRO-C3 215 
Given that univariate and multivariate analyses revealed that the level of PRO-C3 was a strong predictor of 216 
advanced fibrosis, we examined for clinical parameters associated with the level of PRO-C3. It was 217 
subsequently found that ALT (rho 0.29, p=0.0004), AST (rho 0.42, p<0.0001), fasting blood glucose (rho 0.23, 218 
p=0.007), insulin level (rho 0.43, p<0.0001), platelet count (rho -0.24, p=0.004) and presence of diabetes 219 
(rho 0.16, p=0.05) all correlated with the level of PRO-C3 to varying degrees.  220 
 221 
Development of a PRO-C3 based predictive fibrosis score (ADAPT) 222 
Based on the finding that PRO-C3 is strongly associated with fibrosis, we sought to build a model for the 223 
prediction of significant fibrosis based on PRO-C3 and routinely assessed clinical and laboratory variables. 224 
Patients within the derivation cohort were divided into two groups according to NASH CRN fibrosis stage, 225 
F0-2 (no fibrosis to moderate fibrosis) and F3-4 (advanced fibrosis) (Table 3). PRO-C3 was elevated in 226 
patients with advanced fibrosis compared to the mild to moderate group (p<0.0001). Furthermore, those 227 
with advanced fibrosis had significantly increased levels of AST, GGT and a higher AST/ALT ratio (Table 3). 228 
As would be expected, patients with advanced fibrosis had a worse metabolic profile with lower LDL, higher 229 
circulating insulin levels and a higher waist-to-hip ratio (Table 3). The presence of diabetes was more likely 230 
in patients with advanced fibrosis; 67% of patients with F3-4 had diabetes compared to just 29% of the F0-2 231 
group (p=0.002) (Table 3). In addition, patients with advanced fibrosis were found to be older (p=0.02) and 232 
with a lower platelet count compared to those without (p=0.002) (Table 3).  233 
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Variables that were significantly different between the two groups (p<0.05) were considered eligible for the 234 
model building process. Those that described a statistically significant proportion of the variance were 235 
included in the model using the likelihood ratio (LR) test. Ultimately, the variables that were included within 236 
the model, named “ADAPT”, were age, presence of diabetes, platelet count and PRO-C3. 237 
The diagnostic capability of the ADAPT score was assessed via AUROC and was higher than that of PRO-C3 238 
alone, yielding an AUROC of 0.86 (95% CI 0.79-0.91) (Figure 2).  239 
Validation of the diagnostic capabilities of the ADAPT score 240 
To ascertain the validity of our model, the ability of ADAPT to identify patients with advanced fibrosis was 241 
corroborated in a separate cohort comprised of patients from four centers across Asia-Pacific and Europe 242 
(n=281). Several significant differences were identified between the derivation and the validation cohort; 243 
these differences reflect the heterogeneity of NAFLD patients with advanced fibrosis. Despite cohort 244 
differences, the diagnostic accuracy of ADAPT was maintained with an AUROC in the validation cohort of 245 
0.87 (95% CI 0.83-0.91) (Figure 3).  246 
The diagnostic performance of a score, when assessed by AUROC, may vary according to disease 247 
prevalence, known as spectrum bias
30
. The Obuchowski measure accounts for the spectrum bias and 248 
provides a means by which the diagnostic accuracy of a score can be assessed. The Obuchowski measure of 249 
ADAPT within the derivation cohort was calculated to be 0.86 and within the validation cohort it was 0.89. 250 
Additionally, we standardized the AUROC for the distribution of fibrosis stages according to Poynard et al
27
. 251 
The standardized AUROC of ADAPT was found to be 0.89 and 0.89 within the derivation and validation 252 
cohorts, respectively (Table 4). For further confirmation of the generalizability of the model, the validation 253 
cohort was stratified into various groups according to age, (<50, 50-60 and >60), BMI, Sex, NASH vs NAFL 254 
and center. In this analysis, ADAPT remained a robust algorithm in that the AUROC was maintained across 255 
all sub-populations, with NPV consistently exceeding 90% (Supplementary Figure 1).  256 
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Performance of ADAPT against standard algorithms 257 
Within the derivation cohort the AUROC of “ADAPT” (AUROC=0.855) was superior to clinically available 258 
serum based non-invasive scores: APRI (AUROC=0.73, p=0.02), FIB-4 (AUROC=0.78, p=0.06) and NAFLD 259 
Fibrosis Score (AUROC=0.78, p=0.06) (Table 4). Likewise, in the validation cohort, the AUROC of “ADAPT” 260 
(AUROC=0.87) was greater than APRI (AUROC=0.78, p=0.0005), FIB-4 (AUROC=0.85, p=0.32) and NAFLD 261 
Fibrosis Score (AUROC= 0.79, p=0.02) (Table 4). Adjusting the AUROC according to Poynard et al
27
 caused 262 
minor increases in the AUROC in all scores (Table 4). Further investigation into the ability of ADAPT to 263 
identify patients with clinically significant fibrosis (F2-F4) highlighted the superiority of the ADAPT score 264 
when compared to other clinically available serum based non-invasive scores (supplementary table 3). 265 
Derivation of cut-off values  266 
The derivation cohort was subjected to ROC curve analysis to derive a cut-off value for the rule-in and rule-267 
out of advanced fibrosis. A value of >6.3287 for the rule in/out of advanced fibrosis was identified by the 268 
Youden Index, PPV 48.4%, NPV 96.6%, (Supplementary table 2). By applying this cut-off, 73% (n=158) F0-2 269 
patients were correctly classified and 27% (n=58) incorrectly classified. Among F3-4 patients, 92% (n=60) 270 
were correctly classified while 8% (n=5) were incorrectly classified (Table 5). We applied previously derived 271 
cut-off values for APRI (rule in advanced fibrosis >1.5, rule out advanced fibrosis <0.5), FIB-4 (rule in 272 
advanced fibrosis >2.67, rule out advanced fibrosis <1.3) and NAFLD Fibrosis Score (rule in advanced 273 
fibrosis >0.676, rule out advanced fibrosis <-1.455)
10,14,23
. A large proportion of patients fell within an 274 
indeterminate zone, table 5. FIB-4 and APRI showed reasonable performance at identifying patients 275 
without advanced liver fibrosis, 68% (n=147) and 67% (n=145) were correctly classified, respectively. 276 
However, these scores performed poorly at identifying patients with advanced liver fibrosis, NAFLD Fibrosis 277 
Score and FIB-4 correctly identified 51% (n=33) and 46% (n=30) patients, respectively.  278 
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Discussion 279 
In this study, we measured PRO-C3 in NAFLD patients from centers across the world and with a wide 280 
variation in ages and clinical manifestations, similar to that observed in daily clinical practice. The principal 281 
findings were that: 1) PRO-C3 progressively increases with fibrosis severity in NAFLD but that the 282 
association remains highly significant even after adjustment for multiple biochemical and clinical 283 
parameters, and 2) PRO-C3 when combined with routine clinical parameters (ADAPT) generated a highly 284 
accurate tool for the detection of advanced fibrosis in NAFLD. ADAPT is thus a unique score that has utility 285 
for risk stratification and for the clinical management of patients with non-alcoholic fatty liver disease.  286 
Non-invasive biomarkers that reflect the process of hepatic fibrosis are urgently needed; collagen 287 
formation biomarkers are thus attractive targets. Here we demonstrate that PRO-C3, which measures type 288 
III collagen synthesis is a novel and precise marker for advanced liver fibrosis in concordance with what we 289 
have recently shown in chronic hepatitis C
22,31,32
. Notably, a recent small non-biopsy study (n=297) from a 290 
phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) suggested that 291 
PRO-C3 could have utility as a determinant of treatment response to a potential anti-fibrotic therapy
33
. 292 
Karsdal et al (2016) subsequently confirmed this within a study investigating the anti-fibrotic efficacy of 293 
farglitazar
33
; Harrison et al (2018) further explored PRO-C3 as a determinant of treatment response within a 294 
phase IIb study
34
. Though that finding needs to be validated in biopsy proven cohorts, their data in 295 
combination with our findings suggest that PRO-C3 could serve as a biomarker not only for prediction of 296 
fibrosis progression, but also for treatment response. Interestingly, the optimal cut off value in our study 297 
was 15.6 ng/ml for advanced fibrosis, which is significantly different from that in patients with hepatitis C 298 
(20 ng/ml)
35
. Consistently, the cut off level for PRO-C3 was also lower in the BALLET report (13.1 ng/ml)
33
. 299 
Further studies will be required to confirm the optimal cut off in NAFLD. It is noteworthy that the levels of 300 
PRO-C3 did not increase from F3 to F4. The explanation for this finding is not clear and further mechanistic 301 
studies are required. 302 
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Previous reports have suggested that the pro-peptide of type III collagen
22,36
 can be used as a biomarker for 303 
NASH. However, we have shown that PRO-C3 is distinct from PIIINP in that it is a true marker of type III 304 
collagen formation and by extension, fibrogenesis
22
. We subsequently developed a novel PRO-C3-based 305 
fibrosis score for NAFLD patients and compared it to various composite serum based score systems that 306 
have been proposed and tested in NAFLD patients, namely APRI, FIB-4 and the NAFLD Fibrosis Score. The 307 
AUROCs for the various scores examined in this study, all performed similar to previous reports for the 308 
identification of advanced fibrosis
27,37–39
. In contrast, ADAPT was superior, as also in the multi-national 309 
validation cohort. Critically, ADAPT was robust at identifying patients with advanced fibrosis across 310 
different subpopulations (diabetics vs non-diabetics, NAFL vs NASH, various age ranges and BMI categories), 311 
some of which have been shown to confound non-invasive algorithms
40,41
. The AUROC of ADAPT was 312 
maintained at >0.80 for all subpopulations, while the PPV and NPV remained consistent. From a 313 
management perspective, after the application of a derived cut-off value, ADAPT correctly classified 74% of 314 
patients without advanced fibrosis and 92% with advanced fibrosis. Cut-off values for APRI, FIB-4 and 315 
NAFLD Fibrosis Score were applied to our patients; similar to previous reports, we found that a large 316 
proportion of patients fell within an indeterminate zone 
37
. FIB-4 and APRI showed reasonable performance 317 
at identifying patients without advanced fibrosis, but performed poorly at identifying patients with 318 
advanced fibrosis. Furthermore, the superiority of ADAPT is exemplified by its robust performance across 319 
various sub-populations (supplementary table 1) and by the substantially higher NPV. In contrast, the 320 
performance of FIB-4 has been demonstrated to be variable and is affected by confounders such as age. 321 
Additionally, unlike FIB-4, ADAPT is unburdened by the presence of an intermediate zone, which hinders its 322 
accuracy
37,41–44
. An advantage of PRO-C3 used alone or in combination as in ADAPT, is that it may stratify 323 
cirrhosis since the score is on a spectrum. This contrasts with FIB-4 or the NAFLD fibrosis score which are 324 
based on a dichotomous threshold. Hence, PRO-C3 based scores may have potential in patient monitoring 325 
over time, though this needs validation. 326 
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In contrast to the other non-invasive scores, ADAPT is distinct in that it combines PRO-C3 with important 327 
clinical and metabolic parameters associated with disease severity. Both increased age and the presence of 328 
diabetes are well-established risk factors for progressive liver disease and are easily discerned
45
. Similarly, 329 
platelet count is routinely measured and is strongly correlated with liver fibrosis and has been incorporated 330 
into multiple other non-invasive scoring systems
10,12,14
. A study by Mofrad et al has shown that the full 331 
spectrum of liver fibrosis stages can be found in patients presenting with liver enzymes in the normal 332 
range
8
. In addition, liver enzymes are sensitive to age leading to false positive results. Thus, previous 333 
analysis has shown that FIB-4 (and likely also APRI and the NAFLD fibrosis score) cannot be universally 334 
applied without modification to all patient groups
41
. The lack of inclusion of liver enzymes in ADAPT is thus 335 
a conspicuous advantage. 336 
Non-invasive tests have been proposed as screening tools for detecting advanced liver fibrosis in the 337 
general population, where the prevalence of this outcome is low
46
. Score systems such as ADAPT, that 338 
exhibit a high specificity and NPV could provide a useful tool for clinicians as they reduce any uncertainty 339 
surrounding the diagnosis and the number of follow-up assessments required
46
. We propose that the 340 
ADAPT score could be used as such a screening tool within the general population to identify patients at 341 
risk of or with advanced fibrosis, such that interventions could be applied and progression to cirrhosis 342 
perhaps mitigated. However, further validation in non-referral cohorts and demonstration of the cost-343 
effectiveness of using PRO-C3 based score systems is first required.  344 
Our study has some limitations that must be acknowledged. We included well-characterized biopsied 345 
patients from centers with an interest in studying NAFLD, therefore referral bias cannot be ruled out. 346 
Biopsies were read by an independent pathologist at each participating center using a well-defined and 347 
standardized score system. In our hands, the kappa value for assessing the severity of fibrosis has 348 
previously been shown to be good
47
. As previously described by Ratziu et al, liver biopsy as a diagnostic tool 349 
has several limitations including sampling bias
6
. However, all non-invasive diagnostic tools for fibrosis 350 
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assessment are benchmarked against the biopsy. Thus, the use of an imperfect reference standard may 351 
result in underperformance of the accuracy of non-invasive scores. Additionally, due to the nature of this 352 
cross-sectional study, we could not follow the clinical progress of patients; it would be of interest to 353 
investigate the relationship of score classification with patient outcome.  354 
In conclusion, a biomarker score based on PRO-C3 and clinical variables (ADAPT) accurately predicts the 355 
presence or absence of advanced fibrosis in a NAFLD population. Thus, ADAPT could be useful for risk 356 
stratification and management. Further independent studies will be required to determine whether 357 
patients stratification using ADAPT followed by measurement of liver stiffness can replace the need for liver 358 
biopsy as a diagnostic standard in NAFLD.  359 
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Figure 1: PRO-  C3 is highly related to histological parameters of NAFLD Histological staging according to 
Kleiner et al 16. Fibrosis stage (rho=0.50, p<0.0001), Ballooning stage (rho=0.38, p<0.0001), Steatosis 
stage (rho=0.29, p=0.0003), Lobular inflammation (rho=0.36, p<0.0001), Portal inflammation (rho=0.25, 
p=0.003), NAS activity score (rho=0.46, p<0.0001). * p < 0.0332, ** p < 0.0021, *** p < 0.0002, **** p 
< 0.0001)  
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Figure 2: Receiver operating curve (ROC) for the identification of advanced fibrosis by ADAPT within the 
derivation cohort. AUROC = 0.86 (95% CI 0.79 to 0.91).  
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Figure 3: Comparison of various non-invasive serum based scores for the detection of advanced fibrosis 
(F≥3).  
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 Table 1. Characteristics of the total patient population  
 Derivation Cohort Validation Cohort Derivation cohort 
vs Validation cohort 
 n Mean SD n Mean SD P-value 
Age (Years) 150 50.85 12.13 277 52.9 12.38 ns 
Albumin (g/dL) 148 4.403 5.54 277 4.07 0.40 <0.0001 
ALT (IU/L) 148 77.01 50.48 278 69.58 58.43 ns 
AST (IU/L) 149 55.02 35.42 262 46.45 33.40 0.02 
AST/ALT 148 0.79 0.34 220 0.76 0.38 ns 
BMI (kg/m
2
) 145 31.3 5.38 274 34.98 9.54 <0.0001 
Cholesterol (mmol/L) 148 5.21 1.21 198 4.7 1.15 0.0001 
Diabetic 150 37.3%  281 37.4%   ns 
Insulin (mIU/L) 147 17.46 12.7 148 26.37 31.81 0.002 
FBS (mmol/L) 145 6.46 3.10 239 6.54 2.72 ns 
Fibrosis Score 
(0/1/2/3/4) 
42/48/27/25/8  90/87/37/44/21  ns 
Gender (% Female) 150 50.7  281 58  ns 
GGT (IU/L) 148 128 141 256 112.57 160.24 ns 
HDL (mmol/L) 143 1.26 0.41 212 1.2 0.35 0.03 
LDL (mmol/L) 140 3.07 0.99 179 2.78 1.56 ns 
NASH 55   127   ns 
Page 25 of 51
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Platelets (×10
9
/L) 148 244.4 73.53 270 229.7 79.49 ns 
PRO-C3 (ng/mL) 150 20.92 15.48 279 19.93 18.04 ns 
Triglycerides (mmol/L) 149 2.03 1.60 263 1.97 1.40 ns 
Waist/Hip ratio 136 0.97 0.08  41 0.97   0.09 ns 
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Table 3 Predictors of Advanced Fibrosis 
 
F=0-2 F=3-4 
 
 
n Mean SD n Mean SD P 
a
 
Age (Years) 117 49.60 12.28 33 55.30 10.60 0.02 
ALT (IU/L) 116 74.31 45.10 32 86.81 66.44 ns 
AST (IU/L) 117 51.92 33.30 32 66.34 40.87 0.04 
AST/ALT Ratio 116 0.76 0.31 32 0.91 0.39 0.03 
BMI (kg/m
2
) 113 30.99 5.46 32 32.37 4.98 ns 
Diabetes 29%  67%   0.0002
b
 
FBSL (mmol/L) 114 6.49 3.38 31 6.37 1.70 ns 
GGT (IU/L) 116 111.53 124.14 32 187.78 180.08 0.006 
HDL (mmol/L) 114 1.26 0.38 29 1.29 0.49 ns 
Insulin (mIU/L) 115 15.37 10.58 31 25.74 16.25 <0.0001 
LDL (mmol/L) 112 3.19 0.96 28 2.57 0.96 0.002 
Platelets (×10
9
/L) 115 254.17 66.14 33 210.45 87.89 0.002 
PRO-C3 (ng/mL) 117 17.87 13.10 33 31.72 18.42 <0.0001 
TG (mmol/L) 117 2.03 1.61 32 2.03 1.60 ns 
Total cholesterol (mmol/l) 116 5.29 1.12 32 4.89 1.46 ns 
Waist\Hip ratio 106 0.96 0.08 30 1.01 0.06 0.001 
Univariate analysis of variables to identify potential predictors of advanced fibrosis. 
a
 T-test was 
assessed to test for significant differences within continuous variables and 
b
 Fisher’s exact test 
was used for categorical variables 
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Table 4 
  Derivation Cohort  Validation Cohort 
Non-invasive test AUROC AdjAUROC SD 95% CI AUROC AdjAUROC SD 95% CI 
APRI 0.73 0.76 0.05 0.65 to 0.80 0.78 0.80 0.03 0.73 to 0.83 
FIB-4 0.78 0.81 0.05 0.70 to 0.84 0.85 0.87 0.02 0.80 to 0.89 
NAFLD Fibrosis Score 0.78 0.82 0.05 0.71 to 0.85 0.79 0.81 0.03 0.74 to 0.84 
PRO-C3 0.81 0.85 0.04 0.74 to 0.87 0.83 0.84 0.03 0.78 to 0.87 
ADAPT 0.86 0.89 0.04 0.79 to 0.91 0.87 0.89 0.02 0.83 to 0.91 
AUROC-area under the receiver operating curve, SD- standard deviation, 95% CI- 95% confidence intervals 
AdjAUROC- AUROC that has been adjusted according to the Poynard et al  
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Table 5 
 
F0-2 F3-4 
 
Correctly 
Identified Indeterminate 
Incorrectly 
Identified 
Correctly 
Identified Indeterminate 
Incorrectly 
Identified 
∑ 216 65 
APRI 145 63 8 10 36 19 
FIB-4 147 54 15 30 25 10 
NFS 91 100 25 33 25 7 
ADAPT 158 - 58 60 - 5 
Number of patients correctly, incorrectly or indeterminately classified by the various non-
invasive scores 
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Supplementary table 1. Performance of ADAPT and derived cut-off value (6.3287) across various sub-populations   
 NASH NAFL Diabetic Non-
Diabetic 
Male  Female BMI 
18.5-24.9 
BMI 
25-29.9 
BMI 
>30 
Age <50  Age 51-60 Age >60 Storr Liver 
Centre 
Western 
Australia 
Japan UK 
N 127 151 104 137 118 163 26 71 183 107 91 83 47 144 48 42 
F3-4 49 16 39 15 25 40 6 18 41 7 21 37 12 23 12 18 
AUROC 0.81 0.89 0.82 0.86 0.85 0.90 0.87 0.82 0.90 0.88 0.82 0.83 0.79 0.93 0.89 0.75 
Sensitivity 93.9 87.5 94.9 80.0 96.0 90.0 100 94.4 90.2 85.7 85.7 97.3 83.3 91.3 100 94.4 
Specificity 50.0 86.7 52.3 85.2 65.6 78.9 60 66 78.9 87.0 65.7 54.3 77.1 81.8 55.6 50.0 
PPV 54.1 43.8 54.4 39.8 42.9 58.1 42.9 48.6 55.2 31.6 42.9 63.2 55.5 48.8 55.6 58.6 
NPV 92.9 98.3 94.5 97.2 98.4 96.0 100 97.2 96.5 98.9 93.9 96.1 93.1 98.0 100 92.2 
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Supplementary Table 2 
Score value Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) 
>6.3287 90.91 (75.6-98.0) 72.65 (63.6-80.5) 48.4 (21.5-76.0) 96.6 (77.01-100) 
>7.0538 75.76 (57.7-88.9) 80.34 (72.0-87.1) 52.1 (37.2-66.7) 92.2 (85.1-96.6) 
>8.4143 48.48 (30.8-66.5) 92.31 (85.9-96.4) 64 (42.5-82.0) 86.4 (79.1-91.9) 
>9.5261 33.33 (18.0-51.8) 97.44 (92.7-99.5) 78.6 (49.2-95.3) 83.8 (76.5-89.6) 
PPV-positive predictive value, NPV-negative predictive value, 95% CI- 95% confidence intervals 
 
Supplementary Table 3 
Identification of F2-4 within Derivation cohort 
Variable AUC SE 95% CI Vs ADAPT (P=) 
APRI 0.66 0.05 0.58 to 0.73 0.04 
FIB-4 0.68 0.04 0.60 to 0.76 0.04 
NAFLD Fibrosis Score 0.66 0.05 0.58 to 0.74 0.01 
ADAPT 0.76 0.04 0.69 to 0.83 - 
Identification of F2-4 within Validation cohort 
APRI 0.81 0.03 0.75 to 0.85 0.03 
FIB-4 0.82 0.03 0.76 to 0.86 0.04 
NAFLD Fibrosis Score 0.74 0.03 0.68 to 0.79 < 0.0001 
ADAPT 0.86 0.02 0.81 to 0.90 - 
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List of Abbreviations 34 
ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs 35 
ALT: Alanine Aminotransferase 36 
APRI: AST to Platelet Ratio Index 37 
AST: Aspartate Aminotransferase 38 
AUROC: Area under receiver operating curve 39 
BMI: Body mass index 40 
ECM: Extracellular matrix 41 
ELISA: Enzyme-linked immunosorbent assay 42 
GGT: Gamma-Glutamyltransferase 43 
HDL: High-density lipoprotein 44 
LDL: Low-density lipoprotein 45 
LHR+: Positive likelihood ratio  46 
LHR-: Negative likelihood ratio 47 
MS: Metabolic syndrome 48 
NAFL: Non-alcoholic fatty liver 49 
NAFLD: Non-alcoholic fatty liver disease 50 
NASH: Non-alcoholic steatohepatitis 51 
NFS: NAFLD Fibrosis Score 52 
NPV: Negative predictive value 53 
PPV: Positive predictive value 54 
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Abstract  59 
Background and Aim: Given the high global prevalence of non-alcoholic fatty liver disease (NAFLD), the 60 
need for relevant non-invasive biomarkers and algorithms to accurately stage disease severity is a critical 61 
unmet medical need. Identifying those with advanced fibrosis (≥F3) is the most crucial, as these individuals 62 
have the greatest risk of adverse, long-term, liver-related outcomes. We aimed to investigate the role of 63 
PRO-C3 (a marker of type III collagen formation) as a biomarker for advanced fibrosis in NAFLD. Methods: 64 
We measured PRO-C3 by enzyme-linked immunosorbent assay (ELISA) in two large independent cohorts 65 
with extensive clinical phenotyping and liver biopsy; 150 in the derivation and 281 in the validation cohort. 66 
A PRO-C3 based fibrosis algorithm that included Age, presence of DiAbetes, PRO-C3 (a marker of type III 67 
collagen formation), and plaTelet count (“ADAPT”) was developed. Results: PRO-C3 increased with fibrosis 68 
stage (rho 0.50 p<0.0001) and was independently associated with advanced fibrosis (OR=1.05, 95% CI 1.02-69 
1.08, p= 0.003). ADAPT showed areas under the receiver operating characteristics curve (AUROC) of 0.86 70 
(95% CI 0.79 to 0.91) in the derivation and 0.87 in the validation cohort (95% CI 0.83 to 0.91) for advanced 71 
fibrosis. This was superior to the existing fibrosis scores, aspartate aminotransferase (AST) to platelet ratio 72 
index (APRI), FIB-4 and NAFLD fibrosis score (NFS) in most comparisons. Conclusion: PRO-C3 is an 73 
independent predictor of fibrosis stage in NAFLD. A PRO-C3 based score (ADAPT) accurately identifies 74 
patients with NAFLD and advanced fibrosis and is superior to APRI, FIB-4 and NFS. 75 
 76 
Keywords 77 
Biomarker, Extracellular matrix, Non-invasive score, Non-alcoholic fatty liver disease, PRO-C3 78 
Page 35 of 51
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Introduction 79 
The increase in global prevalence of metabolic syndrome (MS) has been accompanied by a rise in organ 80 
damage including end stage disease related to non-alcoholic fatty liver disease (NAFLD). Estimates place the 81 
worldwide prevalence of NAFLD at 25% 
1
. A subset of these patients develop non-alcoholic steatohepatitis 82 
(NASH) that can progress to cirrhosis and are at a high risk of adverse liver-related outcomes
1
. From a 83 
management and therapeutic perspective, an unmet clinical need is the requirement to distinguish those 84 
with early disease from those at highest risk of clinical complications. While metabolic hepatic 85 
inflammation is the milieu that drives disease progression, various studies (including meta analyses) that 86 
have examined for prognostic histological features suggest that fibrosis stage is the parameter that best 87 
associates with overall- and liver-related mortality, as well as liver transplantation and liver related events
2–
88 
5
.  89 
The gold standard for the evaluation of liver fibrosis stage is percutaneous needle biopsy, which is 90 
compromised by inherent sampling and inter-observer biases and peri-procedural risk
6,7
. The invasiveness 91 
and costs of performing biopsies also makes it unsuitable for mass screening, for staging and risk 92 
stratification. The latter is important as the majority of patients with advanced fibrosis and even cirrhosis, 93 
are asymptomatic and often indistinguishable from those at earlier disease stages
8,9
. In this context, there 94 
is a need for surrogate markers of disease stage that can identify and risk stratify patients with NAFLD. This 95 
area of research can broadly be divided into liquid (typically blood based) or physical approaches 96 
(measurement of liver stiffness). Physical approaches while promising are less useful for population level 97 
screening and are limited by cost and other technique-specific considerations. Several serum based 98 
biomarker tests have previously been developed and applied to NAFLD patients
10–14
. These scores typically 99 
combine clinical features and routine laboratory tests and are used primarily to rule out advanced fibrosis
15
, 100 
however they lack sufficient diagnostic accuracy and sensitivity.  101 
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Liver fibrosis is characterized by the accumulation of excess extracellular matrix (ECM) and hence 102 
biomarkers reflecting structural changes occurring in the hepatic ECM during chronic injury may be of value 103 
in the assessment of fibrosis progression or regression. We recently demonstrated that PRO-C3, an 104 
ADAMTS generated neo-epitope marker of type III collagen formation, is a marker of fibrosis in patients 105 
with chronic hepatitis C. The role of PRO-C3 in patients with NAFLD however, is largely unknown. Since the 106 
performance of biomarkers and non-invasive liver fibrosis scores varies widely according to disease etiology, 107 
whether PRO-C3 has a role as a biomarker in NAFLD is unclear. In this study, we sought to a) explore the 108 
association of PRO-C3 with liver fibrosis in two large independent biopsy-proven cohorts with NAFLD and b) 109 
determine if PRO-C3 can be combined with simple and routinely available clinical variables in to a novel 110 
score for the prediction of advanced fibrosis in patients with NAFLD. We compared the performance of our 111 
derived model with other known biomarker algorithms. 112 
 113 
   114 
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Materials and Methods 115 
Study population 116 
A total of 431 well phenotyped patients with biopsy confirmed NAFLD comprised the study cohort. The 117 
derivation cohort included 150 patients from the Storr Liver Centre, Sydney, Australia; the validation cohort 118 
comprised 281 patients recruited from four international sites, Nottingham University Hospitals NHS Trust, 119 
United Kingdom (n=42); Kurume University School of Medicine, Kurume, Japan (n=48); University of 120 
Western Australia, Nedlands, Australia (n=144) and 47 additional patients from the Storr Liver Centre.  121 
All patients were referred for the investigation of abnormal liver tests or steatosis detected by ultrasound. 122 
The diagnosis of NAFLD was established by liver biopsy in all cases. Patients with disease of other etiologies 123 
including viral hepatitis and auto-immune liver disease were excluded by standard clinical, laboratory and 124 
histopathological assessments. Patients with evidence of hepatic decompensation, secondary causes of 125 
steatosis, including excess alcohol (men, >30 g/day; women, >20 g/day), total parenteral nutrition or the 126 
use of drugs known to precipitate steatosis were excluded.  127 
Demographic and clinical data were obtained, including age, gender, ethnicity, height, weight, and waist 128 
circumference at the time of biopsy. Body mass index (BMI) was calculated as BMI = kg/m
2
. Arterial 129 
hypertension was defined as blood pressure ≥130/≥85 mmHg or treatment with antihypertensive drugs. 130 
Diabetes was defined as a fasting blood glucose ≥7.0 mmol/L, previous diagnosis of diabetes or use of anti-131 
diabetic drugs. Hyperlipidemia was defined as fasting total cholesterol >5.5 mmol/L, triglycerides >1.7 132 
mmol/L or treatment with lipid-lowering drugs. Ethical approval and written informed consent from 133 
patients was obtained from all participating centers.  134 
Histology  135 
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All biopsies were routinely stained with hematoxylin & eosin and Masson’s Trichrome. The stained sections 136 
were read and scored by an expert liver pathologist at each participating center using the scoring system 137 
proposed by Kleiner et al., 2005
16
. The stage of liver fibrosis was defined as: stage 0, absence of fibrosis; 138 
stage 1, perisinusoidal or portal fibrosis; stage 2 perisinusoidal and portal/periportal fibrosis; stage 3 septal 139 
or bridging fibrosis; and stage 4 as cirrhosis. A diagnosis of NASH was according to the EASL-EASD-EASO 140 
guidelines.
17
 Thirty-one biopsies were scored independently by pathologists from the various centers, and 141 
inter observer agreement was calculated using the κ statistic and was =0.55 for fibrosis, comparable to 142 
previously published results
18–21
.  143 
Biomarker quantification 144 
At the time of biopsy, a fasting blood sample was obtained and routine biochemical tests were performed 145 
using standard methods and assays. Biochemical tests included albumin, alanine aminotransferase (ALT), 146 
aspartate aminotransferase (AST), total cholesterol, gamma-glutamyltransferase (GGT), insulin, high-147 
density lipoprotein (HDL), low-density lipoprotein (LDL), platelets, and triglycerides.  Additional blood 148 
samples were drawn and frozen at −80°C for future research. Type III collagen formation was assessed in 149 
serum using the PRO-C3 competitive ELISA assay from Nordic Bioscience, Herlev, Denmark, as previously 150 
described
22
.  151 
The APRI, FIB-4 and NAFLD Fibrosis Scores were calculated using clinical and routine laboratory variables 152 
and previously defined algorithms and cut-off values for NAFLD/NASH patients
10,12,14,23
.  153 
Statistical analysis 154 
The main aim of this study was the development of an algorithm comprised of clinical and laboratory 155 
variables that could accurately distinguish patients with advanced fibrosis (F≥3) from those without. To this 156 
end, patients in the derivation cohort were stratified into those with advanced fibrosis (F≥3) and those 157 
without (F0-2). Stage 2 and 3 for lobular and portal inflammation was pooled as only 1 patient in both 158 
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groups was graded stage 3. Continuous variables in the two groups were compared using the t test and 159 
categorical variables were compared using Fisher’s exact test. Comparisons between mean marker levels 160 
were performed using the Kruskal-Wallis test followed by Dunn’s multiple comparison test. Variables that 161 
were significantly different between patients with advanced fibrosis and those without advanced fibrosis 162 
were identified as potential algorithm components.  163 
For the formulation of predictive models, variables showing a p <0.05 at univariate analysis (Student t test 164 
for parametric variables, and X
2
 or Fisher exact test for frequencies) were included. The interaction 165 
between these variables was first tested. Variables explaining a statistically significant proportion of the 166 
variance (p <0.05) were maintained in the model using the likelihood ratio (LR) test. The model variables 167 
were selected using the leave-one-out method to facilitate the calculation of over-fit bias reduced 168 
estimates
24
. To avoid over-fitting, 10-fold cross validations were used in the tree building process. 169 
The model was as following: 170 
 =  	
	 	 × 	⎯3√

  +  
The discriminative ability of the model for the identification of severe fibrosis (F≥3) was assessed by means 171 
of receiver operating characteristic curve analysis and expressed as area under the receiver operating 172 
characteristic curve (AUROC). A cut-off value to distinguish patients with advanced fibrosis from those 173 
without was determined using the bootstrap Youden Index. The diagnostic accuracy of the algorithm and 174 
the derived cut-off was determined by calculating sensitivity, specificity, positive predictive value (PPV) and 175 
negative predictive value (NPV). To overcome both spectrum effect and ordinal scale issues, we undertook 176 
two approaches. Firstly, we used the Obuchowski measure, as proposed by Lambert et al
25,26
, which is a 177 
measure of the probability that two randomly chosen patients from different fibrosis stages are correctly 178 
classified according to the weighted scheme, with a penalty for incorrect classification. In the second 179 
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method, we standardized the AUROC for the distribution of fibrosis stages as proposed by Poynard et al
27
, 180 
as recently described
28
. 181 
ROC curves were also calculated for the established diagnostic scores, APRI, FIB-4 and NAFLD Fibrosis Score. 182 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative 183 
likelihood ratio (LHR
+
, LHR
−
) and 95% CIs were calculated. Estimates of AUROCs and comparisons between 184 
AUROCs were performed using the method suggested by Hanley and McNeil
29
. Validation was subsequently 185 
performed on the validation cohort as well as for the combined overall cohort.  186 
All data are shown as medians and variation expressed via Tukey plots. P-values <5% were considered 187 
significant. Model building and statistical analysis was performed using MedCalc version 16.8.4 (MedCalc 188 
Software, Ostend, Belgium) and SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). Graphs were designed 189 
using GraphPad Prism version 7 (GraphPad Software, Inc., CA, USA).   190 
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Results 191 
Patient Characteristics 192 
The characteristics of the 150 NAFLD patients used to develop the model (derivation cohort) and the 281 193 
used to test the model (validation cohort) are shown in Table 1. Serum levels of albumin, AST, cholesterol 194 
and HDL were all significantly lower in the validation cohort when compared to the derivation cohort. In 195 
addition, both BMI and insulin level were found to be significantly elevated. No other significant differences 196 
were observed between the two cohorts. The prevalence of severe fibrosis was not significantly different 197 
between the cohorts. 198 
PRO-C3 is highly associated with severity of fibrosis and histological parameters 199 
Within the derivation cohort, a neo-epitope marker of type III collagen formation, PRO-C3, was found to be 200 
significantly elevated in patients with advanced fibrosis (F≥3) compared to the mild/moderate group 201 
(p<0.0001). PRO-C3 was highly associated with disease severity (Figure 1) and moderately correlated to the 202 
severity of fibrosis (rho = 0.501, p<0.0001). PRO-C3 was able to discriminate between the following stages 203 
of fibrosis (Figure 1): F0 versus F2 (27% increase, p<0.0332), F0 versus F3 (54% increase, p<0.0001), F1 204 
versus F3 (36% increase, p<0.0002) and F0 versus F4 (57% increase, p<0.0021). In addition, PRO-C3 205 
discriminated between the various stages of hepatocyte ballooning (stage 0 versus stage 1 p=0.001, stage 0 206 
versus 2 p=0.0003), lobular inflammation (stage 0 versus stage 1 p=0.0004, stage 0 versus stage 2 and 3 207 
p=0.0008) and steatosis (stage 1 versus stage 3 p=0.003).  208 
We undertook logistic regression to discern the effect of various clinical variables on the association of 209 
PRO-C3 with the presence of advanced fibrosis (F≥3) within the derivation cohort. In this analysis, PRO-C3, 210 
when adjusted for age, ALT, AST, BMI, ballooning, lobular inflammation, presence of diabetes, GGT and 211 
platelet count, was independently associated with advanced fibrosis (OR=1.054, 95% CI 1.01-1.07) (Table 2). 212 
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The area under the receiver-operating curve (AUROC) for the identification of patients with advanced 213 
fibrosis (F≥3) of PRO-C3 alone was 0.81 (95% CI 0.74-0.87) (Data not shown).  214 
Clinical parameters associated with the level of PRO-C3 215 
Given that univariate and multivariate analyses revealed that the level of PRO-C3 was a strong predictor of 216 
advanced fibrosis, we examined for clinical parameters associated with the level of PRO-C3. It was 217 
subsequently found that ALT (rho 0.29, p=0.0004), AST (rho 0.42, p<0.0001), fasting blood glucose (rho 0.23, 218 
p=0.007), insulin level (rho 0.43, p<0.0001), platelet count (rho -0.24, p=0.004) and presence of diabetes 219 
(rho 0.16, p=0.05) all correlated with the level of PRO-C3 to varying degrees.  220 
Development of a PRO-C3 based predictive fibrosis score (ADAPT) 221 
Based on the finding that PRO-C3 is strongly associated with fibrosis, we sought to build a model for the 222 
prediction of significant fibrosis based on PRO-C3 and routinely assessed clinical and laboratory variables. 223 
Patients within the derivation cohort were divided into two groups according to NASH CRN fibrosis stage, 224 
F0-2 (no fibrosis to moderate fibrosis) and F3-4 (advanced fibrosis) (Table 3). PRO-C3 was elevated in 225 
patients with advanced fibrosis compared to the mild to moderate group (p<0.0001). Furthermore, those 226 
with advanced fibrosis had significantly increased levels of AST, GGT and a higher AST/ALT ratio (Table 3). 227 
As would be expected, patients with advanced fibrosis had a worse metabolic profile with lower LDL, higher 228 
circulating insulin levels and a higher waist-to-hip ratio (Table 3). The presence of diabetes was more likely 229 
in patients with advanced fibrosis; 67% of patients with F3-4 had diabetes compared to just 29% of the F0-2 230 
group (p=0.002) (Table 3). In addition, patients with advanced fibrosis were found to be older (p=0.02) and 231 
with a lower platelet count compared to those without (p=0.002) (Table 3).  232 
Variables that were significantly different between the two groups (p<0.05) were considered eligible for the 233 
model building process. Those that described a statistically significant proportion of the variance were 234 
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included in the model using the likelihood ratio (LR) test. Ultimately, the variables that were included within 235 
the model, named “ADAPT”, were age, presence of diabetes, platelet count and PRO-C3. 236 
The diagnostic capability of the ADAPT score was assessed via AUROC and was higher than that of PRO-C3 237 
alone, yielding an AUROC of 0.86 (95% CI 0.79-0.91) (Figure 2).  238 
Validation of the diagnostic capabilities of the ADAPT score 239 
To ascertain the validity of our model, the ability of ADAPT to identify patients with advanced fibrosis was 240 
corroborated in a separate cohort comprised of patients from four centers across Asia-Pacific and Europe 241 
(n=281). Several significant differences were identified between the derivation and the validation cohort; 242 
these differences reflect the heterogeneity of NAFLD patients with advanced fibrosis. Despite cohort 243 
differences, the diagnostic accuracy of ADAPT was maintained with an AUROC in the validation cohort of 244 
0.87 (95% CI 0.83-0.91) (Figure 3).  245 
The diagnostic performance of a score, when assessed by AUROC, may vary according to disease 246 
prevalence, known as spectrum bias
30
. The Obuchowski measure accounts for the spectrum bias and 247 
provides a means by which the diagnostic accuracy of a score can be assessed. The Obuchowski measure of 248 
ADAPT within the derivation cohort was calculated to be 0.86 and within the validation cohort it was 0.89. 249 
Additionally, we standardized the AUROC for the distribution of fibrosis stages according to Poynard et al
27
. 250 
The standardized AUROC of ADAPT was found to be 0.89 and 0.89 within the derivation and validation 251 
cohorts, respectively (Table 4). For further confirmation of the generalizability of the model, the validation 252 
cohort was stratified into various groups according to age, (<50, 50-60 and >60), BMI, Sex, NASH vs NAFL 253 
and center. In this analysis, ADAPT remained a robust algorithm in that the AUROC was maintained across 254 
all sub-populations, with NPV consistently exceeding 90% (Supplementary Figure 1).  255 
Performance of ADAPT against standard algorithms 256 
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Within the derivation cohort the AUROC of “ADAPT” (AUROC=0.855) was superior to clinically available 257 
serum based non-invasive scores: APRI (AUROC=0.73, p=0.02), FIB-4 (AUROC=0.78, p=0.06) and NAFLD 258 
Fibrosis Score (AUROC=0.78, p=0.06) (Table 4). Likewise, in the validation cohort, the AUROC of “ADAPT” 259 
(AUROC=0.87) was greater than APRI (AUROC=0.78, p=0.0005), FIB-4 (AUROC=0.85, p=0.32) and NAFLD 260 
Fibrosis Score (AUROC= 0.79, p=0.02) (Table 4). Adjusting the AUROC according to Poynard et al
27
 caused 261 
minor increases in the AUROC in all scores (Table 4). Further investigation into the ability of ADAPT to 262 
identify patients with clinically significant fibrosis (F2-F4) highlighted the superiority of the ADAPT score 263 
when compared to other clinically available serum based non-invasive scores (supplementary table 3). 264 
Derivation of cut-off values  265 
The derivation cohort was subjected to ROC curve analysis to derive a cut-off value for the rule-in and rule-266 
out of advanced fibrosis. A value of >6.3287 for the rule in/out of advanced fibrosis was identified by the 267 
Youden Index, PPV 48.4%, NPV 96.6%, (Supplementary table 2). By applying this cut-off, 73% (n=158) F0-2 268 
patients were correctly classified and 27% (n=58) incorrectly classified. Among F3-4 patients, 92% (n=60) 269 
were correctly classified while 8% (n=5) were incorrectly classified (Table 5). We applied previously derived 270 
cut-off values for APRI (rule in advanced fibrosis >1.5, rule out advanced fibrosis <0.5), FIB-4 (rule in 271 
advanced fibrosis >2.67, rule out advanced fibrosis <1.3) and NAFLD Fibrosis Score (rule in advanced 272 
fibrosis >0.676, rule out advanced fibrosis <-1.455)
10,14,23
. A large proportion of patients fell within an 273 
indeterminate zone, table 5. FIB-4 and APRI showed reasonable performance at identifying patients 274 
without advanced liver fibrosis, 68% (n=147) and 67% (n=145) were correctly classified, respectively. 275 
However, these scores performed poorly at identifying patients with advanced liver fibrosis, NAFLD Fibrosis 276 
Score and FIB-4 correctly identified 51% (n=33) and 46% (n=30) patients, respectively.  277 
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Discussion 278 
In this study, we measured PRO-C3 in NAFLD patients from centers across the world and with a wide 279 
variation in ages and clinical manifestations, similar to that observed in daily clinical practice. The principal 280 
findings were that: 1) PRO-C3 progressively increases with fibrosis severity in NAFLD but that the 281 
association remains highly significant even after adjustment for multiple biochemical and clinical 282 
parameters, and 2) PRO-C3 when combined with routine clinical parameters (ADAPT) generated a highly 283 
accurate tool for the detection of advanced fibrosis in NAFLD. ADAPT is thus a unique score that has utility 284 
for risk stratification and for the clinical management of patients with non-alcoholic fatty liver disease.  285 
Non-invasive biomarkers that reflect the process of hepatic fibrosis are urgently needed; collagen 286 
formation biomarkers are thus attractive targets. Here we demonstrate that PRO-C3, which measures type 287 
III collagen synthesis is a novel and precise marker for advanced liver fibrosis in concordance with what we 288 
have recently shown in chronic hepatitis C
22,31,32
. Notably, a recent small non-biopsy study (n=297) from a 289 
phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) suggested that 290 
PRO-C3 could have utility as a determinant of treatment response to a potential anti-fibrotic therapy
33
. 291 
Karsdal et al (2016) subsequently confirmed this within a study investigating the anti-fibrotic efficacy of 292 
farglitazar
33
; Harrison et al (2018) further explored PRO-C3 as a determinant of treatment response within a 293 
phase IIb study
34
. Though that finding needs to be validated in biopsy proven cohorts, their data in 294 
combination with our findings suggest that PRO-C3 could serve as a biomarker not only for prediction of 295 
fibrosis progression, but also for treatment response. Interestingly, the optimal cut off value in our study 296 
was 15.6 ng/ml for advanced fibrosis, which is significantly different from that in patients with hepatitis C 297 
(20 ng/ml)
35
. Consistently, the cut off level for PRO-C3 was also lower in the BALLET report (13.1 ng/ml)
33
. 298 
Further studies will be required to confirm the optimal cut off in NAFLD. It is noteworthy that the levels of 299 
PRO-C3 did not increase from F3 to F4. The explanation for this finding is not clear and further mechanistic 300 
studies are required. 301 
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Previous reports have suggested that the pro-peptide of type III collagen
22,36
 can be used as a biomarker for 302 
NASH. However, we have shown that PRO-C3 is distinct from PIIINP in that it is a true marker of type III 303 
collagen formation and by extension, fibrogenesis
22
. We subsequently developed a novel PRO-C3-based 304 
fibrosis score for NAFLD patients and compared it to various composite serum based score systems that 305 
have been proposed and tested in NAFLD patients, namely APRI, FIB-4 and the NAFLD Fibrosis Score. The 306 
AUROCs for the various scores examined in this study, all performed similar to previous reports for the 307 
identification of advanced fibrosis
27,37–39
. In contrast, ADAPT was superior, as also in the multi-national 308 
validation cohort. Critically, ADAPT was robust at identifying patients with advanced fibrosis across 309 
different subpopulations (diabetics vs non-diabetics, NAFL vs NASH, various age ranges and BMI categories), 310 
some of which have been shown to confound non-invasive algorithms
40,41
. The AUROC of ADAPT was 311 
maintained at >0.80 for all subpopulations, while the PPV and NPV remained consistent. From a 312 
management perspective, after the application of a derived cut-off value, ADAPT correctly classified 74% of 313 
patients without advanced fibrosis and 92% with advanced fibrosis. Cut-off values for APRI, FIB-4 and 314 
NAFLD Fibrosis Score were applied to our patients; similar to previous reports, we found that a large 315 
proportion of patients fell within an indeterminate zone 
37
. FIB-4 and APRI showed reasonable performance 316 
at identifying patients without advanced fibrosis, but performed poorly at identifying patients with 317 
advanced fibrosis. Furthermore, the superiority of ADAPT is exemplified by its robust performance across 318 
various sub-populations (supplementary table 1) and by the substantially higher NPV. In contrast, the 319 
performance of FIB-4 has been demonstrated to be variable and is affected by confounders such as age. 320 
Additionally, unlike FIB-4, ADAPT is unburdened by the presence of an intermediate zone, which hinders its 321 
accuracy
37,41–44
. An advantage of PRO-C3 used alone or in combination as in ADAPT, is that it may stratify 322 
cirrhosis since the score is on a spectrum. This contrasts with FIB-4 or the NAFLD fibrosis score which are 323 
based on a dichotomous threshold. Hence, PRO-C3 based scores may have potential in patient monitoring 324 
over time, though this needs validation. 325 
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In contrast to the other non-invasive scores, ADAPT is distinct in that it combines PRO-C3 with important 326 
clinical and metabolic parameters associated with disease severity. Both increased age and the presence of 327 
diabetes are well-established risk factors for progressive liver disease and are easily discerned
45
. Similarly, 328 
platelet count is routinely measured and is strongly correlated with liver fibrosis and has been incorporated 329 
into multiple other non-invasive scoring systems
10,12,14
. A study by Mofrad et al has shown that the full 330 
spectrum of liver fibrosis stages can be found in patients presenting with liver enzymes in the normal 331 
range
8
. In addition, liver enzymes are sensitive to age leading to false positive results. Thus, previous 332 
analysis has shown that FIB-4 (and likely also APRI and the NAFLD fibrosis score) cannot be universally 333 
applied without modification to all patient groups
41
. The lack of inclusion of liver enzymes in ADAPT is thus 334 
a conspicuous advantage. 335 
Non-invasive tests have been proposed as screening tools for detecting advanced liver fibrosis in the 336 
general population, where the prevalence of this outcome is low
46
. Score systems such as ADAPT, that 337 
exhibit a high specificity and NPV could provide a useful tool for clinicians as they reduce any uncertainty 338 
surrounding the diagnosis and the number of follow-up assessments required
46
. We propose that the 339 
ADAPT score could be used as such a screening tool within the general population to identify patients at 340 
risk of or with advanced fibrosis, such that interventions could be applied and progression to cirrhosis 341 
perhaps mitigated. However, further validation in non-referral cohorts and demonstration of the cost-342 
effectiveness of using PRO-C3 based score systems is first required.  343 
Our study has some limitations that must be acknowledged. We included well-characterized biopsied 344 
patients from centers with an interest in studying NAFLD, therefore referral bias cannot be ruled out. 345 
Biopsies were read by an independent pathologist at each participating center using a well-defined and 346 
standardized score system. In our hands, the kappa value for assessing the severity of fibrosis has 347 
previously been shown to be good
47
. As previously described by Ratziu et al, liver biopsy as a diagnostic tool 348 
has several limitations including sampling bias
6
. However, all non-invasive diagnostic tools for fibrosis 349 
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assessment are benchmarked against the biopsy. Thus, the use of an imperfect reference standard may 350 
result in underperformance of the accuracy of non-invasive scores. Additionally, due to the nature of this 351 
cross-sectional study, we could not follow the clinical progress of patients; it would be of interest to 352 
investigate the relationship of score classification with patient outcome.  353 
In conclusion, a biomarker score based on PRO-C3 and clinical variables (ADAPT) accurately predicts the 354 
presence or absence of advanced fibrosis in a NAFLD population. Thus, ADAPT could be useful for risk 355 
stratification and management. Further independent studies will be required to determine whether 356 
patients stratification using ADAPT followed by measurement of liver stiffness can replace the need for liver 357 
biopsy as a diagnostic standard in NAFLD.  358 
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